I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
"While rapidly advancing the clinical development of lemzoparlimab, we continue to pursue the full clinical potential of lemzoparlimab and validating its combination strategies through preclinical and translational research," said Dr.
The accepted abstracts are currently available on the ASH website:
Title: |
Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) |
Abstract ID: |
3974 |
Presenter: |
Prof. Chunkang Chang, |
Session: |
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III |
Location: |
|
Date/Time: |
|
Abstract synopsis: The data show an increased calreticulin (CALR) expression in CD33+ blasts after lemzoparlimab and AZA combination treatment and higher immune infiltrates including total, CD91+ macrophages and CD8/Treg ratio in bone marrow at baseline is associated with better clinical response, suggesting the important role of activation of tumor derived pro-phagocytic signal and effector immune cells in the anti-tumor activity mediated by combination treatment. In addition, patients whose malignancy harbors a TP53 mutation showed a higher CALR expression and immune infiltrates in bone marrow, which may be related with the observed better clinical response than those with wild type (WT) TP53. Our results pinpoint the potential mechanism of clinical benefits from lemzoparlimab and AZA treatment in HR-MDS.
Title: |
Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma |
Abstract ID: |
4462 |
Presenter: |
Dr. |
Session: |
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III |
Location: |
|
Date/Time: |
|
Abstract synopsis: In this research we found that high CD47 and low CD38 expression was related with poor clinical outcome in relapsed or refractory multiple myeloma (rrMM) patients especially those high-risk populations. Combination of lemzoparlimab and felzartamab showed enhanced in vitro antibody-dependent cellular phagocytosis (ADCP) and in vivo anti-tumor efficacy in these CD47-high and CD38-low high-risk MM which was resistant to felzartamab or daratumumab mono-treatment. Our study provides preclinical evidence to explore the combination of lemzoparlimab and felzartamab in the treatment of high-risk MM patients.
Additional data collected will be included in final meeting presentations. Both posters will be made available on the Company's website following the close of ASH annual meeting on
About CD47 and Lemzoparlimab
CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a "don't eat me" signal to otherwise tumor-engulfing macrophages. CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at
Multiple clinical studies of lemzoparlimab are ongoing to explore indications in treating patients with myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), non-Hodgkin's lymphoma (NHL), and advanced solid tumors in combination with chemotherapy and immune checkpoint inhibitors.
About Felzartamab
Felzartamab (TJ202/MOR202) is an investigational human monoclonal antibody derived from MorphoSys' HuCAL® antibody technology. The antibody is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells. According to its suggested mode of action, the antibody recruits cells of the body's immune system to kill the tumor through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The antibody does not involve complement dependent cytotoxicity, or
HuCAL® is a registered trademark of MorphoSys AG.
About
I-Mab Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from preclinical studies of lemzoparlimab, the potential implications of clinical data for patients, and
I-Mab Contacts Chief Operating Officer, interim Chief Financial Officer |
|
Investor Inquiries |
E-mail: emilie@thepiacentegroup.com Office line: +86 21 6039 8363 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-two-poster-presentations-of-cd47-antibody-lemzoparlimab-at-ash-2022-301667270.html
SOURCE